MX357780B - Derivados policíclicos, proceso para su preparación y su uso farmacéutico. - Google Patents

Derivados policíclicos, proceso para su preparación y su uso farmacéutico.

Info

Publication number
MX357780B
MX357780B MX2014008125A MX2014008125A MX357780B MX 357780 B MX357780 B MX 357780B MX 2014008125 A MX2014008125 A MX 2014008125A MX 2014008125 A MX2014008125 A MX 2014008125A MX 357780 B MX357780 B MX 357780B
Authority
MX
Mexico
Prior art keywords
preparation
derivatives
medical uses
polycyclic derivatives
general formula
Prior art date
Application number
MX2014008125A
Other languages
English (en)
Other versions
MX2014008125A (es
Inventor
Wang Yang
Dong Qing
Yang Fanglong
Han Jihui
Wang Chunfei
Zhang Ling
Original Assignee
Jiangsu Hengrui Medicine Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co filed Critical Jiangsu Hengrui Medicine Co
Publication of MX2014008125A publication Critical patent/MX2014008125A/es
Publication of MX357780B publication Critical patent/MX357780B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80Radicals substituted by oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring

Abstract

En la presente invención se describen derivados policíclicos representados por la fórmula general (I), el método de preparación de los mismos, composiciones farmacéuticas que contiene los derivados y usos de los mismos como agentes terapéuticos, especialmente el agonista de GPR40 y en la preparación de fármacos para el tratamiento de enfermedades como la diabetes y los trastornos metabólicos, etc., en donde cada sustituyente en la fórmula general (I) tiene la misma definición que en la descripción. (ver Fórmula).
MX2014008125A 2012-01-12 2012-12-27 Derivados policíclicos, proceso para su preparación y su uso farmacéutico. MX357780B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201210008286 2012-01-12
PCT/CN2012/087606 WO2013104257A1 (zh) 2012-01-12 2012-12-27 多环类衍生物、其制备方法及其在医药上的应用

Publications (2)

Publication Number Publication Date
MX2014008125A MX2014008125A (es) 2014-09-22
MX357780B true MX357780B (es) 2018-07-24

Family

ID=48781054

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014008125A MX357780B (es) 2012-01-12 2012-12-27 Derivados policíclicos, proceso para su preparación y su uso farmacéutico.

Country Status (15)

Country Link
US (1) US9139548B2 (es)
EP (1) EP2803664B1 (es)
JP (1) JP6122871B2 (es)
KR (1) KR102036547B1 (es)
CN (1) CN103429581B (es)
AU (1) AU2012365706B2 (es)
BR (1) BR112014016648B1 (es)
CA (1) CA2860353A1 (es)
HK (1) HK1188781A1 (es)
MX (1) MX357780B (es)
RU (1) RU2621039C1 (es)
TW (1) TWI588136B (es)
UA (1) UA115975C2 (es)
WO (1) WO2013104257A1 (es)
ZA (1) ZA201404625B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104592211B (zh) * 2013-10-31 2018-10-16 广东东阳光药业有限公司 联苯类化合物及其用途
CN104650055A (zh) * 2013-11-22 2015-05-27 山东轩竹医药科技有限公司 芳香多环羧酸衍生物
CN104788412B (zh) * 2014-01-22 2017-02-15 山东轩竹医药科技有限公司 芳香多环羧酸衍生物
WO2016019587A1 (en) 2014-08-08 2016-02-11 Merck Sharp & Dohme Corp. [7, 6]-fused bicyclic antidiabetic compounds
US10662171B2 (en) 2014-08-08 2020-05-26 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
US10100042B2 (en) 2014-08-08 2018-10-16 Merck Sharp & Dohme Corp. [5,6]—fused bicyclic antidiabetic compounds
EP3177287B1 (en) 2014-08-08 2022-02-23 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2016059042A1 (de) 2014-10-14 2016-04-21 Basf Se Verwendung von hexadeca-8,15-dienal als aromachemikalie
CN106478616B (zh) * 2015-08-27 2020-05-12 江苏恒瑞医药股份有限公司 一种gpr40激动剂的结晶形式及其制备方法
CN108236611A (zh) * 2016-12-27 2018-07-03 江苏恒瑞医药股份有限公司 两种化合物联合在制备治疗糖尿病药物中的用途
CN108236609B (zh) * 2016-12-27 2022-10-21 江苏恒瑞医药股份有限公司 一种gpr40激动剂药物组合物及其制备方法
WO2019160882A1 (en) 2018-02-13 2019-08-22 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
TWI712412B (zh) 2018-04-19 2020-12-11 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
KR20230159715A (ko) 2018-07-13 2023-11-21 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
CN112955435A (zh) 2018-10-24 2021-06-11 吉利德科学公司 Pd-1/pd-l1抑制剂
CA3156985A1 (en) 2019-10-07 2021-04-15 Kallyope, Inc. Gpr119 agonists
CA3178994A1 (en) 2020-05-19 2021-11-25 Iyassu Sebhat Ampk activators
CN116390925A (zh) 2020-06-26 2023-07-04 卡尔优普公司 Ampk活化剂
CN114163426B (zh) * 2020-09-10 2024-03-19 上海爱博医药科技有限公司 苯并含氧杂环类化合物及其医药应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2138498C1 (ru) * 1994-07-22 1999-09-27 Бык Гульден Ломберг Хемише Фабрик Гмбх Дигидробензофураны, способ их получения и фармацевтическая композиция на их основе
EP1630152A4 (en) * 2003-05-30 2009-09-23 Takeda Pharmaceutical CONNECTION WITH CONDENSED RING
CA2536089A1 (en) 2003-08-20 2005-03-03 Eli Lilly And Company Ppar modulators
WO2005051890A1 (en) 2003-11-19 2005-06-09 Smithkline Beecham Corporation Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to gpr40
RU2006126978A (ru) * 2003-12-25 2008-01-27 Такеда Фармасьютикал Компани Лимитед (Jp) Производные 3-(4-бензилоксифенил)пропановой кислоты
JP4074616B2 (ja) * 2003-12-25 2008-04-09 武田薬品工業株式会社 3−(4−ベンジルオキシフェニル)プロパン酸誘導体
WO2005087710A1 (ja) 2004-03-15 2005-09-22 Takeda Pharmaceutical Company Limited アミノフェニルプロパン酸誘導体
US20060014785A1 (en) * 2004-05-25 2006-01-19 Metabolex, Inc. Bicyclic, substituted triazoles as modulators of ppar and methods of their preparation
WO2007106469A2 (en) * 2006-03-14 2007-09-20 Amgen Inc. Bicyclic carboxylic acid derivatives useful for treating metabolic disorders
CN103070854A (zh) 2006-06-27 2013-05-01 武田药品工业株式会社 稠环化合物
WO2010048207A2 (en) * 2008-10-21 2010-04-29 Metabolex, Inc. Aryl gpr120 receptor agonists and uses thereof
AR074760A1 (es) * 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
MX2011008059A (es) 2009-01-30 2011-10-11 Toyama Chemical Co Ltd Derivado del acido n-acil antranilico o sal del mismo.
BRPI1013937A2 (pt) * 2009-04-22 2016-08-09 Astellas Pharma Inc compostos de ácido carboxílico
JP5657578B2 (ja) 2009-06-09 2015-01-21 武田薬品工業株式会社 新規な縮合環化合物およびその用途
CN102153553A (zh) 2010-02-11 2011-08-17 山东轩竹医药科技有限公司 含有氨基磺酰胺基氮杂环丁烷的口服碳青霉烯化合物
US8299117B2 (en) * 2010-06-16 2012-10-30 Metabolex Inc. GPR120 receptor agonists and uses thereof

Also Published As

Publication number Publication date
BR112014016648B1 (pt) 2020-10-27
BR112014016648A8 (pt) 2017-07-04
TWI588136B (zh) 2017-06-21
JP6122871B2 (ja) 2017-04-26
ZA201404625B (en) 2015-11-25
BR112014016648A2 (pt) 2017-06-13
US9139548B2 (en) 2015-09-22
MX2014008125A (es) 2014-09-22
CN103429581B (zh) 2015-08-26
US20150005282A1 (en) 2015-01-01
CA2860353A1 (en) 2013-07-18
AU2012365706A1 (en) 2014-07-24
EP2803664A1 (en) 2014-11-19
KR20140117498A (ko) 2014-10-07
AU2012365706B2 (en) 2015-08-20
HK1188781A1 (zh) 2014-05-16
EP2803664B1 (en) 2018-11-21
CN103429581A (zh) 2013-12-04
EP2803664A4 (en) 2015-10-28
TW201329058A (zh) 2013-07-16
UA115975C2 (uk) 2018-01-25
WO2013104257A1 (zh) 2013-07-18
KR102036547B1 (ko) 2019-10-25
RU2621039C1 (ru) 2017-05-31
JP2015503595A (ja) 2015-02-02

Similar Documents

Publication Publication Date Title
MX357780B (es) Derivados policíclicos, proceso para su preparación y su uso farmacéutico.
MX2019005379A (es) Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo.
MX2019010354A (es) Derivado de heteroaril[4,3-c]pirimidina-5-amina, metodo de preparacion del mismo y usos medicos del mismo.
PH12015501385A1 (en) Autotaxin inhibitors
MX2015010971A (es) Derivado novedoso de pirazol.
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
MX2015003653A (es) Derivados de amida del acido benzoimidazol-carboxilico como moduladores del receptor apj.
WO2013188792A3 (en) Neuroactive steroids, compositions, and uses thereof
BR112015000578A2 (pt) moduladores da via do complemento e usos dos mesmos
UA113051C2 (xx) Гетероциклічні похідні та їх застосування у лікуванні неврологічних розладів
UA109868C2 (ru) Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar)
MX2014009757A (es) Derivados de isoindolina, composiciones farmaceuticas que los contienen y su uso en terapia.
MY189427A (en) Pyrazolyl quinoxaline kinase inhibitors
MX2013011086A (es) (aralquilamino y heteroarilalquilamino alfa-sustituidos)pirimidini lo y 1,3,5-triazinilbenzimidazoles, composiciones farmacéuticas que los contienen, y estos compuestos para su uso en el tratamiento de enfermedades proliferativas.
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
MX360554B (es) Composiciones que comprenden y metodos que utilizan inhibidores de co-transportadores de glucosa-sodio 1 y 2.
DOP2014000059A (es) Derivados de estra–1,3,5(10),16–tetraen–3–carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
BR112013026257A2 (pt) derivados de glicosídeo e usos dos mesmos para o tratamento de diabetes
EA201201658A1 (ru) Производные пиперидина и их применение для лечения метаболических нарушений
WO2013061004A8 (fr) Nouveaux composés di-substitués de la diamino-3,4-cyclobutène-3-dione-1,2 utiles dans le traitement de pathologies médiées par des chimiokines
WO2013040227A3 (en) Therapeutic compounds
ECSP15000868A (es) Derivados de estra–1,3,5(10),16–tetraeno 3–sustituidos, métodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos
BR112014012459A2 (pt) 2h-indazóis como antagonistas do receptor de ep2
MY168212A (en) A new therapeutical composition containing apomorphine as active ingredient
GEP20156332B (en) Pyrazoles as crth2 antagonists

Legal Events

Date Code Title Description
FG Grant or registration